Midostaurin – Multi-Targeted FLT3 and KIT Kinase Inhibitor Therapy

Midostaurin is a systemic antineoplastic agent formulated as a multi-targeted protein kinase inhibitor (a targeted small-molecule, semi-synthetic derivative of staurosporine). The mechanism of action of midostaurin involves competitive inhibition of adenosine triphosphate (ATP) binding to the catalytic domains of numerous receptor and non-receptor tyrosine kinases. The drug exhibits a prominent affinity for mutant and wild-type forms of the FLT3 receptor (Fms-like tyrosine kinase 3), including internal tandem duplication (FLT3-ITD) types and tyrosine kinase domain (FLT3-TKD) mutations. Blockade of FLT3 halts constitutive intracellular signaling cascades, inducing cell cycle arrest and apoptosis within leukemic cell lines. Furthermore, midostaurin effectively suppresses the activity of KIT receptors (both wild-type and the mutant D816V isoform), stem cell factor receptors, vascular endothelial growth factor receptors VEGFR-1 and VEGFR-2, and various protein kinase C (PKC) isoforms, thereby preventing uncontrolled mast cell proliferation and angiogenesis.

The clinical uniqueness of midostaurin lies in its established ability to radically alter the prognosis of aggressive hematological malignancies that were historically deemed highly treatment-resistant. Combined with standard induction chemotherapy (daunorubicin and cytarabine), it significantly prolongs overall survival in patients presenting with newly diagnosed FLT3-mutation-positive acute myeloid leukemia (AML). The drug also serves as an indispensable first-line option for advanced systemic mastocytosis (ASM), mast cell leukemia, and systemic mastocytosis associated with an underlying hematological non-mast cell lineage disease (SM-AHN). Following oral administration, midostaurin demonstrates substantial absorption when co-administered with high-fat meals. It binds extensively and almost completely (~99.8%) to plasma proteins. It undergoes predominant hepatic biotransformation via the CYP3A4 isoenzyme to form two major active metabolites (CGP62221 and CGP52421), with the concentrations of the long-lived metabolite CGP52421 greatly exceeding those of the parent drug during steady-state dosing. The elimination half-life is approximately 20–21 hours for midostaurin and up to 36 days for the CGP52421 metabolite. Systemic clearance occurs mainly through the feces (95%) as metabolites.

The drug is administered orally. Initiating therapy mandates prior genetic confirmation of the FLT3 mutation status in patients with AML. Ongoing treatment requires strict, regular laboratory monitoring of complete blood counts, biochemical panels (including electrolytes, lipase, and liver function parameters), ECG tracking of the QT interval, and consistent respiratory monitoring due to risks of pulmonary toxicity.

Wikipedia page
Midostaurin

Indications

Midostaurin is indicated for the systemic targeted therapy of adult patients presenting with the following malignant hematological disorders:

  • Acute Myeloid Leukemia (AML): comprehensive management in combination with standard induction chemotherapy (daunorubicin and cytarabine) and consolidation chemotherapy (high-dose cytarabine) in patients with newly diagnosed FLT3-mutation-positive acute myeloid leukemia.
  • Advanced Systemic Mastocytosis (ASM): monotherapy for patients with aggressive systemic mastocytosis presenting with extensive organ damage and multi-organ dysfunction.
  • Systemic Mastocytosis with an Associated Hematological Disease: management of systemic mastocytosis accompanied by a secondary clonal hematological non-mast cell lineage disease (SM-AHN).
  • Mast Cell Leukemia (MCL): therapy for the highly aggressive neoplastic presentation of mast cell leukemia.

Dosage and administration

The dosing regimen of midostaurin is customized based on the clinical diagnosis, concurrent chemotherapy protocols, and individual patient tolerability, requiring cyclic or continuous administration.

  • Dose in Acute Myeloid Leukemia (AML): the recommended dose is 50 mg (two 25 mg capsules) taken orally twice daily (totaling 100 mg per day). During the induction and consolidation phases, the drug is administered from Day 8 through Day 21 of each 28-day chemotherapy cycle. For subsequent maintenance monotherapy, the drug is taken continuously and daily for up to 12 cycles.
  • Dose in Advanced Systemic Mastocytosis and Mast Cell Leukemia: the recommended dose for continuous regimen is 100 mg taken orally twice daily (totaling 200 mg per day). Treatment is maintained continuously as long as clinical benefit is observed or until unacceptable toxicity develops.
  • Administration Method: capsules must be swallowed whole with a glass of water and never chewed. The drug must be taken with food (ideally a meal of standard fat content) twice daily at approximately 12-hour intervals. This administration schedule significantly mitigates the severity of gastrointestinal side effects.
  • Missed Dose and Vomiting: if a scheduled dose is missed, the patient should skip it and take the next dose at its regular time on the following day. If vomiting occurs after capsule ingestion, an additional dose must not be administered; the regular dosing schedule should be resumed.
  • Dose Modifications for Toxicity: in the event of severe neutropenia, thrombocytopenia, QT interval prolongation exceeding 500 ms, or pulmonary toxicity, midostaurin therapy should be temporarily interrupted or down-titrated until clinical resolution occurs.

The use of midostaurin is restricted by substantial risks of systemic toxicities, severe drug interactions, and significant teratogenic potential, and is contraindicated in the following clinical states:

  • Hypersensitivity: documented history of anaphylaxis or individual hypersensitivity to midostaurin or any inactive formulation excipients inside the dosage form.
  • Concomitant Therapy Interactions: concurrent administration with potent CYP3A4 isoenzyme inducers (such as rifampicin, carbamazepine, phenytoin, or St. John's wort) is contraindicated due to the risk of critical plasma level reductions, rendering midostaurin ineffective.
  • Pregnancy: midostaurin possesses established teratogenic and embryofetotoxic properties. Use during pregnancy is strictly contraindicated. Females of reproductive potential must employ highly effective contraceptive methods during therapy and for at least 4 months following the final dose.
  • Lactation: data regarding midostaurin excretion into human breast milk are unavailable, but potential risks to the infant are severe. Breastfeeding is completely contraindicated during treatment and for at least 4 months after receiving the final dose.
  • Age Restrictions: safety, tolerability, and efficacy profiles of midostaurin in children and adolescents under 18 years of age have not been established; use within the pediatric cohort is not recommended.

The side effects of midostaurin are highly prominent and necessitate close monitoring due to overlapping toxicities with concurrent cytotoxic chemotherapy regimens:

  • Hematological Toxicity: very frequently reported events include severe febrile neutropenia, lymphopenia, leukopenia, thrombocytopenia, and anemia.
  • Gastrointestinal Disorders: extremely frequent events include prominent nausea, vomiting, diarrhea, stomatitis, mucositis, abdominal pain, constipation, and dysgeusia.
  • Respiratory System: very frequently reported upper respiratory tract infections, cough, dyspnea; rarely, development of interstitial lung disease or pneumonitis may occur.
  • Cardiovascular Disturbances: ECG QT interval prolongation, sinus tachycardia, hypertension or hypotension, and peripheral edema.
  • Dermatological and General Reactions: exfoliative dermatitis, petechiae, skin rash, alopecia, hyperhidrosis, fatigue, pyrexia, and headache.
  • Laboratory Parameters: transient elevations in plasma ALT, AST, alkaline phosphatase, and bilirubin levels, alongside hyperglycemia and increased plasma lipase or amylase activity.

Frequently Asked Questions

Midostaurin is an oral, multi-targeted small-molecule tyrosine kinase inhibitor that blocks multiple cell-surface receptors regulating hematopoietic proliferation and survival. Its primary therapeutic targets include both mutant variants of the FLT3 receptor (including internal tandem duplication, FLT3-ITD, and tyrosine kinase domain, FLT3-TKD, mutations) as well as wild-type and mutant KIT receptors (notably the D816V mutation). By inhibiting these specific kinases, midostaurin disrupts downstream oncogenic signaling pathways, leading to cell cycle arrest and apoptosis in malignant blasts and mast cells.
Midostaurin is indicated for the treatment of adult patients with two distinct hematological conditions. First, it is indicated for newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, administered in combination with standard induction (daunorubicin and cytarabine) and consolidation chemotherapy. Second, it is indicated as a monotherapy for advanced systemic mastocytosis, which encompasses aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia.
The standard dosage depends on the clinical indication: for FLT3-mutant AML, the dose is 50 mg (two 25 mg capsules) orally twice daily on specified days of chemotherapy cycles; for advanced systemic mastocytosis, the dose is 100 mg twice daily continuously. Midostaurin capsules must be administered strictly with food at 12-hour intervals and swallowed whole. Because midostaurin is highly emetogenic, prophylactic antiemetic therapy should be routinely administered 30 to 60 minutes prior to each dose to enhance patient tolerance and prevent severe nausea.
Midostaurin therapy carries a risk of rare but severe and potentially fatal pulmonary toxicities, including interstitial lung disease (ILD) and pneumonitis. Patients must be carefully monitored for emergent respiratory changes. At the very first onset or worsening of pulmonary symptoms such as cough, dyspnea, wheezing, or hypoxia, midostaurin must be immediately withheld. If a diagnostic workup (such as a chest CT scan) confirms drug-induced pneumonitis or ILD, midostaurin must be permanently discontinued.
Midostaurin administration is associated with a high incidence of severe neutropenia, febrile neutropenia, and anemia, which demands mandatory weekly complete blood count monitoring, particularly during initial cycles. From a cardiovascular perspective, the drug can prolong the QTc interval on an ECG, elevating the risk of ventricular arrhythmias. Patients require continuous electrocardiogram monitoring, serum electrolyte checks, and periodic assessments of left ventricular ejection fraction via echocardiograms, particularly when co-administered with potent CYP3A4 inhibitors.

List of medicines by active substance

-6%
Rydapt 25 mg Novartis
View
Novartis

Rydapt

Midostaurin
25 mg 112 capsules
133100₴ 141973₴
✅ All products loaded (1)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00